<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03563157</url>
  </required_header>
  <id_info>
    <org_study_id>QUILT-3.071</org_study_id>
    <nct_id>NCT03563157</nct_id>
  </id_info>
  <brief_title>QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine</brief_title>
  <official_title>NANT Colorectal Cancer (CRC) Vaccine: A Phase 1b/2 Trial of the NANT CRC Vaccine vs Regorafenib in Subjects With Metastatic CRC Who Have Been Previously Treated With Standard-of-Care Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunityBio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImmunityBio, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      QUILT 3.071 NANT Colorectal Cancer (CRC) Vaccine: Phase 1b/2 NANT CRC Vaccine vs Regorafenib&#xD;
      in Subjects with CRC Who have Previously Treated with SOC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NANT Colorectal Cancer (CRC) Vaccine: A phase 1b/2 Trial of the NANT CRC Vaccine vs&#xD;
      Regorafenib in Subjects with Metastatic CRC Who Have Been Previously Treated with&#xD;
      Standard-Of-Care Therapy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 25, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent AEs and SAEs, graded using the NCI CTCAE Version 4.03</measure>
    <time_frame>2 years</time_frame>
    <description>Phase 1b</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival from baseline to progression, per RECIST 1.1</measure>
    <time_frame>2 years</time_frame>
    <description>Phase 2 Randomized Component</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate, as determined by the percentage of patients achieving Partial or Complete Response per RECIST 1.1</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 2 Single Arm Component</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR for Phase 1b and Phase 2 Randomized Component</measure>
    <time_frame>1 year</time_frame>
    <description>Overall Response Rate, as determined by the percentage of patients achieving Partial or Complete response per RECIST 1.1 and irRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS for Phase 1b and Phase 2 Single Arm Component</measure>
    <time_frame>2 years</time_frame>
    <description>Progression Free Survival from baseline to progression per RECIST 1.1 and irRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component</measure>
    <time_frame>2 years</time_frame>
    <description>Overall Survival from first treatment to date of death (any cause)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component</measure>
    <time_frame>2 years</time_frame>
    <description>Duration of Response from date of first response to date of disease progression or death (any cause), per RECIST 1.1 and irRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component</measure>
    <time_frame>1 year</time_frame>
    <description>Disease Control Rate: the number of patients with a CR, PR or SD lasting at least 2 months per RECIST 1.1 and irRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component</measure>
    <time_frame>2 years</time_frame>
    <description>Quality of Life as assessed by Patient Reported Outcomes using the FACT-C questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">332</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <condition>mCRC</condition>
  <arm_group>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A combination of agents will be administered to subjects in this study: Aldoxorubicin HCI, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, N-803, Avelumab, Capecitabine, Cetuximab, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Nab-paclitaxel, Oxaliplatin, Regorafenib, SBRT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regorafenib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In subjects with metastatic CRC who have been previously treated with standard-of-care (SOC) therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aldoxorubicin Hydrochloride</intervention_name>
    <description>Aldoxorubicin Hydrochloride HCI</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALT-803</intervention_name>
    <description>Recombinant human super agonist interleukin-15 (IL-15) complex [also known as IL-15N72D;IL-15RaSu/IgG1 Fe complex1]</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETBX-011</intervention_name>
    <description>Ad5 [E1-, E2b-]-CEA</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETBX-021</intervention_name>
    <description>Ad5 [E1-, E2b-]-[HER2]</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETBX-051</intervention_name>
    <description>Ad5 [E1-, E2b-]-Brachyury</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETBX-061</intervention_name>
    <description>Ad5 [E1-, E2b-]-mucin 1 [MUC1]</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI-4000</intervention_name>
    <description>RAS yeast</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI-6207</intervention_name>
    <description>CEA yeast</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI-6301</intervention_name>
    <description>Brachyury yeast</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>haNK</intervention_name>
    <description>haNK™, NK-92 [CD16.158V, ER IL-2]</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>BAVENCIO® injection</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>XELODA® tablets</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>ERBITUX® injection</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide Capsules</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil</intervention_name>
    <description>5-FU; Fluorouracil Injection</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Leucovorin Calcium</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>ABRAXANE® for Injectable Suspension [paclitaxel protein-bound particles for injectable suspension] [albumin-bound]</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>ELOXATIN® injection</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib</intervention_name>
    <description>STIVARGA® tablets</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
    <arm_group_label>Regorafenib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>Stereotactic body radiation therapy</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years.&#xD;
&#xD;
          2. Able to understand and provide a signed informed consent that fulfills the relevant&#xD;
             IRB or IEC guidelines.&#xD;
&#xD;
          3. Histologically-confirmed recurrent or metastatic CRC previously treated with&#xD;
             fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF&#xD;
             biological therapy, and if RAS wild-type, an anti-EGFR therapy; or subjects who are&#xD;
             ineligible for these therapies.&#xD;
&#xD;
          4. ECOG performance status of 0 or 1.&#xD;
&#xD;
          5. Have at least 1 measurable lesion of ≥ 1.0 cm.&#xD;
&#xD;
          6. Must have a recent FFPE tumor biopsy specimen following the conclusion of the most&#xD;
             recent anticancer treatment and be willing to release the specimen for prospective and&#xD;
             exploratory tumor molecular profiling. If an historic specimen is not available, the&#xD;
             subject must be willing to undergo a biopsy during the screening period, if considered&#xD;
             safe by the Investigator. If safety concerns preclude collection of a biopsy during&#xD;
             the screening period, a tumor biopsy specimen collected prior to the conclusion of the&#xD;
             most recent anticancer treatment may be used.&#xD;
&#xD;
          7. Must be willing to provide blood samples prior to the start of treatment on this study&#xD;
             for prospective tumor molecular profiling and exploratory analyses.&#xD;
&#xD;
          8. Must be willing to provide a tumor biopsy specimen 8 weeks after the start of&#xD;
             treatment for exploratory analyses, if considered safe by the Investigator.&#xD;
&#xD;
          9. Ability to attend required study visits and return for adequate follow-up, as required&#xD;
             by this protocol.&#xD;
&#xD;
         10. Agreement to practice effective contraception for female subjects of child-bearing&#xD;
             potential and non-sterile males. Female subjects of child-bearing potential must agree&#xD;
             to use effective contraception for up to 1 year after completion of therapy, and non-&#xD;
             sterile male subjects must agree to use a condom for up to 4 months after treatment.&#xD;
             Effective contraception includes surgical sterilization (eg, vasectomy, tubal&#xD;
             ligation), two forms of barrier methods (eg, condom, diaphragm) used with spermicide,&#xD;
             IUDs, and abstinence.&#xD;
&#xD;
             Phase 2 single-arm component only&#xD;
&#xD;
         11. Must have progressed on or after regorafenib treatment in the randomized phase 2&#xD;
             portion of the study OR progressed or experienced unacceptable toxicity on SoC and&#xD;
             regorafenib prior to enrollment on the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. MSI-high or MMR-deficient tumors eligible for, but not yet treated with, a PD-1&#xD;
             inhibitor.&#xD;
&#xD;
          2. Serious uncontrolled concomitant disease that would contraindicate the use of the&#xD;
             investigational drugs used in this study or that would put the subject at high risk&#xD;
             for treatment-related complications.&#xD;
&#xD;
          3. Systemic autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's&#xD;
             disease, or autoimmune disease associated with lymphoma).&#xD;
&#xD;
          4. History of organ transplant requiring immunosuppression.&#xD;
&#xD;
          5. History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative&#xD;
             colitis).&#xD;
&#xD;
          6. Inadequate organ function, evidenced by the following laboratory results:&#xD;
&#xD;
               1. ANC &lt; 1,000 cells/mm^3.&#xD;
&#xD;
               2. Uncorrectable grade 3 anemia (hemoglobin &lt; 8 g/dL)&#xD;
&#xD;
               3. Platelet count &lt; 75,000 cells/mm^3.&#xD;
&#xD;
               4. Total bilirubin &gt; ULN (unless the subject has documented Gilbert's syndrome).&#xD;
&#xD;
               5. AST (SGOT) or ALT (SGPT) &gt; 2.5 × ULN (&gt; 5 × ULN in subjects with liver&#xD;
                  metastases).&#xD;
&#xD;
               6. ALP &gt; 2.5 × ULN (&gt; 5 × ULN in subjects with liver metastases, or &gt;10 × ULN in&#xD;
                  subjects with bone metastases).&#xD;
&#xD;
               7. Serum creatinine &gt; 2.0 mg/dL or 177 μmol/L.&#xD;
&#xD;
               8. Serum anion gap &gt; 16 mEq/L or arterial blood with pH &lt; 7.3.&#xD;
&#xD;
          7. Uncontrolled hypertension (systolic &gt; 160 mm Hg and/or diastolic &gt; 110 mm Hg) or&#xD;
             clinically significant (ie, active) cardiovascular disease, cerebrovascular&#xD;
             accident/stroke, or myocardial infarction within 6 months prior to first study&#xD;
             medication; unstable angina; congestive heart failure of New York Heart Association&#xD;
             grade 2 or higher; or serious cardiac arrhythmia requiring medication. Subjects with&#xD;
             uncontrolled hypertension should be medically managed on a stable regimen to control&#xD;
             hypertension prior to study entry.&#xD;
&#xD;
          8. Serious myocardial dysfunction defined by ECHO as absolute LVEF 10% below the&#xD;
             institution's lower limit of predicted normal.&#xD;
&#xD;
          9. Dyspnea at rest due to complications of advanced malignancy or other disease requiring&#xD;
             continuous oxygen therapy.&#xD;
&#xD;
         10. Positive results of screening test for HIV.&#xD;
&#xD;
         11. Current chronic daily treatment (continuous for &gt; 3 months) with systemic&#xD;
             corticosteroids (dose equivalent to or greater than 10 mg/day methylprednisolone),&#xD;
             excluding inhaled steroids. Short-term steroid use to prevent IV contrast allergic&#xD;
             reaction or anaphylaxis in subjects who have known contrast allergies is allowed.&#xD;
&#xD;
         12. Known hypersensitivity to any component of the study medication(s).&#xD;
&#xD;
         13. Subjects taking any medication(s) (herbal or prescribed) known to have an adverse drug&#xD;
             reaction with any of the study medications.&#xD;
&#xD;
         14. Concurrent or prior use of a strong CYP3A4 inhibitor (including ketoconazole,&#xD;
             itraconazole, posaconazole, clarithromycin, indinavir, nefazodone, nelfinavir,&#xD;
             ritonavir, saquinavir, telithromycin, voriconazole, and grapefruit products) or strong&#xD;
             CYP3A4 inducers (including phenytoin, carbamazepine, rifampin, rifabutin, rifapentin,&#xD;
             phenobarbital, and St John's Wort) within 14 days before study day 1.&#xD;
&#xD;
         15. Concurrent or prior use of a strong CYP2C8 inhibitor (gemfibrozil) or moderate CYP2C8&#xD;
             inducer (rifampin) within 14 days before study day 1.&#xD;
&#xD;
         16. Participation in an investigational drug study or history of receiving any&#xD;
             investigational treatment within 30 days prior to screening for this study, except for&#xD;
             testosterone-lowering therapy in men with prostate cancer.&#xD;
&#xD;
         17. Assessed by the Investigator to be unable or unwilling to comply with the requirements&#xD;
             of the protocol.&#xD;
&#xD;
         18. Concurrent participation in any interventional clinical trial.&#xD;
&#xD;
         19. Pregnant and nursing women.&#xD;
&#xD;
             Phase 2 randomized component only&#xD;
&#xD;
         20. Prior regorafenib treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chan Soon-Shiong Institute for Medicine</name>
      <address>
        <city>El Segundo</city>
        <state>California</state>
        <zip>90245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 22, 2018</study_first_submitted>
  <study_first_submitted_qc>June 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Metastatic Colorectal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Avelumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

